Overview
Sponsor-declared trial summary
Atrial Fibrillation
To evaluate if milvexian is non-inferior to apixaban for the composite of stroke and non-CNS systemic embolism.
Key facts
- Sponsor
- Janssen - Cilag International
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 23 Aug 2023 → ongoing
- Decision date (initial)
- 2023-08-07
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
External identifiers
- EU CT number
- 2022-501419-15-00
- ClinicalTrials.gov
- NCT05757869
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Safety, Pharmacodynamic, Prophylaxis, Pharmacokinetic, Therapy, Efficacy, Pharmacoeconomic
To evaluate if milvexian is non-inferior to apixaban for the composite of stroke and non-CNS systemic embolism.
Secondary objectives 6
- To evaluate if milvexian is superior to apixaban in reducing risk of the principal safety endpoint family: • ISTH major bleeding • Composite of ISTH major and CRNM bleeding
- To evaluate if milvexian is superior to apixaban as assessed by the composite of the primary efficacy endpoint and the principal safety endpoint.
- To evaluate if milvexian is superior to apixaban for the composite of CV death, MI, stroke and non-CNS systemic embolism.
- To evaluate if milvexian is superior to apixaban as assessed by CV death.
- To evaluate if milvexian is superior to apixaban as assessed by the composite of all-cause death, MI, stroke and non-CNS systemic embolism.
- To evaluate if milvexian is superior to apixaban as assessed by the composite of CV death, MI, stroke, acute limb ischemia (ALI [any unanticipated revascularization or amputation of ischemic limb]), and urgent hospitalization for vascular cause of ischemic nature (including thrombotic events: deep vein thrombosis [DVT] and pulmonary embolism [PE]).
Conditions and MedDRA coding
Atrial Fibrillation
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 20.0 | PT | 10003658 | Atrial fibrillation | 100000004849 |
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency
- Plan to share IPD
- Yes
- IPD plan description
- The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 4
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation therapy.
- Participant must satisfy one or both of the following categories of risk factors (a or b): a. One or more of the following risk factors: i. Age ≥75 years ii. History of any type of stroke, including symptomatic stroke of any kind and silent brain infarcts or cerebral microbleeds b. Two or more of the following risk factors: i. Age between 65 and 74 years ii. Hypertension iii. Diabetes mellitus iv. Atherosclerotic vascular disease v. Heart Failure
Exclusion criteria 2
- Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Time to the first occurrence of composite endpoint of stroke and non-CNS systemic embolism
Secondary endpoints 6
- • Time to the first occurrence of ISTH major bleeding • Time to the first occurrence of the composite of ISTH major and CRNM bleeding
- Time to the first occurrence of composite endpoint of stroke, non-CNS systemic embolism, and ISTH major bleeding.
- Time to the first occurrence of composite endpoint of CV death, MI, stroke, and non-CNS systemic embolism.
- Time to CV death
- Time to the first occurrence of composite endpoint of all-cause death, MI, stroke and non-CNS systemic embolism.
- Time to the first occurrence of composite endpoint of CV death, MI, stroke, acute limb ischemia (ALI [any unanticipated revascularization or amputation of ischemic limb]), and urgent hospitalization for vascular cause of ischemic nature (including DVT and PE).
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 1
PRD10075928 · Product
- Active substance
- Milvexian
- Substance synonyms
- BMS986177, BMS-986177, (5R,9S)-9-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxopyrimidin-1(6H)-yl}-22-(difluoromethyl)-5-methyl-22H-3-aza-1(4,2)-pyridina-2(3,4)-pyrazolacyclononaphan-4-one, JNJ-70033093
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 200 mg milligram(s)
- Max total dose
- 292000 mg milligram(s)
- Max treatment duration
- 48 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- JANSSEN-CILAG INTERNATIONAL N.V.
- Paediatric formulation
- No
- Orphan designation
- No
Comparator 4
Eliquis 5 mg film-coated tablets
PRD2351268 · Product
- Active substance
- Apixaban
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 10 mg milligram(s)
- Max total dose
- 14600 mg milligram(s)
- Max treatment duration
- 48 Month(s)
- Authorisation status
- Authorised
- ATC code
- B01AF02 — -
- Marketing authorisation
- EU/1/11/691/012
- MA holder
- BRISTOL-MYERS SQUIBB/PFIZER EEIG
- MA country
- Iceland
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- Yes
- Modification description
- The film-coated tablets will be supplied as over-encapsulated capsules.
Eliquis 5 mg film-coated tablets
PRD2351289 · Product
- Active substance
- Apixaban
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 10 mg milligram(s)
- Max total dose
- 14600 mg milligram(s)
- Max treatment duration
- 48 Month(s)
- Authorisation status
- Authorised
- ATC code
- B01AF02 — -
- Marketing authorisation
- EU/1/11/691/011
- MA holder
- BRISTOL-MYERS SQUIBB/PFIZER EEIG
- MA country
- Iceland
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- Yes
- Modification description
- The film-coated tablets will be supplied as over-encapsulated capsules.
Eliquis 2.5 mg film-coated tablets
PRD1722226 · Product
- Active substance
- Apixaban
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 5 mg milligram(s)
- Max total dose
- 7300 mg milligram(s)
- Max treatment duration
- 48 Month(s)
- Authorisation status
- Authorised
- ATC code
- B01AF02 — -
- Marketing authorisation
- EU/1/11/691/015
- MA holder
- BRISTOL-MYERS SQUIBB/PFIZER EEIG
- MA country
- EU
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- Yes
- Modification description
- The film-coated tablets will be supplied as over-encapsulated capsules.
Eliquis 2.5 mg film-coated tablets
PRD2351318 · Product
- Active substance
- Apixaban
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 5 mg milligram(s)
- Max total dose
- 7300 mg milligram(s)
- Max treatment duration
- 48 Month(s)
- Authorisation status
- Authorised
- ATC code
- B01AF02 — -
- Marketing authorisation
- EU/1/11/691/013
- MA holder
- BRISTOL-MYERS SQUIBB/PFIZER EEIG
- MA country
- Iceland
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- Yes
- Modification description
- The film-coated tablets will be supplied as over-encapsulated capsules.
Placebo 2
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Auxiliary 3
Ondexxya 200 mg powder for solution for infusion
PRD9745324 · Product
- Active substance
- Andexanet Alfa
- Pharmaceutical form
- SOLUTION FOR INFUSION
- Route of administration
- INTRAVENOUS
- Max daily dose
- 1760 mg milligram(s)
- Max total dose
- 1760 mg milligram(s)
- Max treatment duration
- 1 Day(s)
- Authorisation status
- Authorised
- ATC code
- V03AB38 — -
- Marketing authorisation
- EU/1/18/1345/001
- MA holder
- ASTRAZENECA AB
- MA country
- Iceland
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
Eliquis 5 mg film-coated tablets
PRD2351290 · Product
- Active substance
- Apixaban
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 10 mg milligram(s)
- Max total dose
- 300 mg milligram(s)
- Max treatment duration
- 30 Day(s)
- Authorisation status
- Authorised
- ATC code
- B01AF02 — -
- Marketing authorisation
- EU/1/11/691/009
- MA holder
- BRISTOL-MYERS SQUIBB/PFIZER EEIG
- MA country
- Iceland
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
Eliquis 2.5 mg film-coated tablets
PRD2351250 · Product
- Active substance
- Apixaban
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL
- Max daily dose
- 5 mg milligram(s)
- Max total dose
- 150 mg milligram(s)
- Max treatment duration
- 30 Day(s)
- Authorisation status
- Authorised
- ATC code
- B01AF02 — -
- Marketing authorisation
- EU/1/11/691/003
- MA holder
- BRISTOL-MYERS SQUIBB/PFIZER EEIG
- MA country
- Iceland
- Paediatric formulation
- No
- Orphan designation
- No
- Modified vs. Marketing Authorisation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Janssen - Cilag International
- Sponsor organisation
- Janssen - Cilag International
- Address
- Turnhoutseweg 30
- City
- Beerse
- Postcode
- 2340
- Country
- Belgium
Scientific contact point
- Organisation
- Janssen - Cilag International
- Contact name
- CTIS Point of Contact
Public contact point
- Organisation
- Janssen - Cilag International
- Contact name
- CTIS Point of Contact
Third parties 11
| Organisation | City, country | Duties |
|---|---|---|
| Eresearchtechnology Inc. ORG-100013039
|
Philadelphia, United States | Other |
| Cisys Inc. ORG-100046011
|
Raleigh, United States | Other |
| Iqvia Limited ORG-100008655
|
Reading, United Kingdom | On site monitoring, Code 10, Code 12, Code 13, Code 2, Code 5, Code 8, Code 9 |
| Olink Proteomics AB ORG-100045757
|
Uppsala, Sweden | Laboratory analysis |
| Pharmaceutical Research Associates Group B.V. ORG-100006268
|
Assen, Netherlands | Laboratory analysis |
| IQVIA RDS Hellas Single Member S.A ORL-000000587
|
Athens, Greece | On site monitoring, Code 12, Code 8 |
| Medidata Solutions Inc. ORG-100016256
|
New York, United States | E-data capture |
| Omnitrace Corp. ORG-100045579
|
Palm Beach Gardens, United States | Other |
| Olink Proteomics Inc. ORG-100046440
|
Waltham, United States | Laboratory analysis |
| Almac Clinical Technologies LLC ORG-100043036
|
Souderton, United States | Interactive response technologies (IRT) |
| Labcorp Central Laboratory Services S.a.r.l. Meyrin ORG-100011524
|
Meyrin, Switzerland | Laboratory analysis |
Locations
19 EU/EEA countries · 372 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Belgium | Ongoing, recruitment ended | 109 | 13 |
| Bulgaria | Ongoing, recruitment ended | 1,348 | 37 |
| Croatia | Ongoing, recruitment ended | 110 | 11 |
| Czechia | Ongoing, recruitment ended | 687 | 30 |
| Denmark | Ongoing, recruitment ended | 178 | 9 |
| Estonia | Ongoing, recruitment ended | 34 | 1 |
| France | Ongoing, recruitment ended | 103 | 15 |
| Germany | Ongoing, recruitment ended | 656 | 41 |
| Greece | Ongoing, recruitment ended | 52 | 11 |
| Hungary | Ongoing, recruitment ended | 1,090 | 34 |
| Italy | Ongoing, recruitment ended | 279 | 20 |
| Latvia | Ongoing, recruitment ended | 26 | 3 |
| Lithuania | Ongoing, recruitment ended | 182 | 8 |
| Netherlands | Ongoing, recruitment ended | 369 | 23 |
| Poland | Ongoing, recruitment ended | 1,982 | 56 |
| Portugal | Ongoing, recruitment ended | 115 | 8 |
| Romania | Ongoing, recruitment ended | 330 | 17 |
| Slovakia | Ongoing, recruitment ended | 399 | 19 |
| Spain | Ongoing, recruitment ended | 190 | 16 |
| Rest of world
China, New Zealand, Israel, Malaysia, India, Singapore, Brazil, South Africa, United Kingdom, Chile, Serbia, Turkey, Korea, Republic of, Japan, Argentina, Taiwan, Philippines, Canada, Australia, United States
|
— | 11,520 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Belgium | 2023-09-27 | 2023-09-27 | 2025-01-17 | ||
| Bulgaria | 2023-08-23 | 2023-08-23 | 2025-01-17 | ||
| Croatia | 2024-01-30 | 2024-01-30 | 2025-01-17 | ||
| Czechia | 2023-09-05 | 2023-09-05 | 2025-01-17 | ||
| Denmark | 2023-10-09 | 2023-10-09 | 2025-01-17 | ||
| Estonia | 2023-10-10 | 2023-10-10 | 2025-01-17 | ||
| France | 2023-10-12 | 2023-10-12 | 2025-01-17 | ||
| Germany | 2023-09-06 | 2023-09-06 | 2025-01-17 | ||
| Greece | 2024-06-17 | 2024-06-17 | 2025-01-17 | ||
| Hungary | 2023-08-31 | 2023-08-31 | 2025-01-17 | ||
| Italy | 2023-10-04 | 2023-10-04 | 2025-01-17 | ||
| Latvia | 2024-05-02 | 2024-05-02 | 2025-01-17 | ||
| Lithuania | 2023-09-04 | 2023-09-04 | 2025-01-17 | ||
| Netherlands | 2023-09-07 | 2023-09-20 | 2025-01-17 | ||
| Poland | 2023-09-13 | 2023-09-13 | 2025-01-17 | ||
| Portugal | 2023-09-29 | 2023-09-29 | 2025-01-17 | ||
| Romania | 2023-09-07 | 2023-09-07 | 2025-01-17 | ||
| Slovakia | 2023-09-07 | 2023-09-07 | 2025-01-17 | ||
| Spain | 2023-11-22 | 2023-11-22 | 2025-01-17 |
Oversight and notifications
Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77
Serious breaches 1 · Art. 52 CTR
Serious breach SB-48327
- Sponsor became aware
- 2024-09-19
- Date of breach
- 2024-09-11
- Submission date
- 2025-06-24
- Member states concerned
- Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Romania, Spain, Netherlands, Poland, Slovakia
- Categories
- Protocol
- Areas impacted
- Subject safety
- Benefit-risk balance changed
- No
- Description
- As per the protocol of Study 70033093AFL3002 (LIBREXIA AF) in participants with atrial fibrillation (AF) or flutter, participants receiving an anticoagulant indicated for AF before study entry should be instructed to discontinue previous anticoagulation therapy before starting the study treatment of blinded milvexian or apixaban, due to the potential of increased risk of bleeding. As per Protocol, participants who received a direct oral anticoagulant (DOAC) or a vitamin K antagonist before study entry should be instructed to discontinue previous anticoagulation therapy. Additional chronic anticoagulants (e.g. VKA, Factor IIa or FXa inhibitors) are prohibited concomitant therapies.
The initial incidence of a participant receiving double coagulation therapy was discovered during a routine site monitoring visit (SMV) at a site in Germany in Sep 2024. While reporting this incident as a major protocol deviation, it was noted that there was a similar protocol deviation for another participant at the same site in April 2024. A quality investigation was initiated and a total of 4 incidents, 2 participants at the above-mentioned site in Germany, and 1 participant each at a site in Denmark and a site in Japan were identified as having taken the prohibited double coagulation therapy for AF for at least 5 days and outside of a medically supervised setting. These 4 incidents were included in the initial report. Based on review of all identified incidents, there were no reports of any bleeding events, or adverse events during the time of double anticoagulant administration.
All impacted sites were immediately notified and planned retraining at the time the protocol deviations were discovered. Sponsor has continued ongoing surveillance and implemented appropriate mitigations as needed. - Sponsor actions
- All sites with identified incidents were immediately notified and the Sponsor planned re-training when the issue was discovered. All of the identified incidents have been recorded as Major Protocol Deviations.
To prevent additional incidents, Sponsor sent out reminders, developed a mandatory training module for all participating sites, and made an enhancement to the Interactive Web Response System (IWRS) to increase awareness of this potential error.
Sponsor will continue surveillance of concomitant anticoagulants throughout the duration of the trial.
| Organisation | City | Country | Type |
|---|---|---|---|
| Vivantes Netzwerk fuer Gesundheit GmbH | Berlin | Germany | Clinical investigator |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 489 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Protocol_EL_2022-501419-15-00_Redacted | Am 3 |
| Protocol (for publication) | D1_Protocol_EN_2022-501419-15-00_Redacted | Am 3 |
| Protocol (for publication) | D4_Patient Facing Document_EQ-5D-5L_ePRO_Layout | 1.00 |
| Protocol (for publication) | D4_Patient Facing Document_EQ-5D-5L_ePRO_Layout_LV | 1.0 |
| Protocol (for publication) | D4_Patient Facing Document_EQ-5D-5LIA_ePRO_Layout_LV | 1.0 |
| Protocol (for publication) | D4_Patient Facing Document_EQ-5D-5LIT_ePRO_Layout | 1.00 |
| Protocol (for publication) | D4_Patient Facing Document_PROMIS29_ePRO_Layout | 1.00 |
| Protocol (for publication) | D4_Patient Facing Document_PROMIS29_ePRO_Layout_LV | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_BEFR_Digital Interviewer_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_BEFR_Patient_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_BENL_Digital Interviewer_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_BENL_Patient_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_DE_Digital Interviewer_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_DE_Patient_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_EL_Patient_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_EL_Telephone Interviewer_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_ES_Digital Interview_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_ES_Patient_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_FR_Digital Interviewer_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_FR_Patient_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_HR_Digital Interviewer_2022-501419-15-00 | 0.01 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_HR_Patient_2022-501419-15-00 | 0.01 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_HU_Digital Interviewer_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_HU_Patient_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_IT_Digital Interviewer_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_IT_Patient_2022-501419-15-00 | 1.0 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_LT_Digital Interview_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_LT_Patient_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_LTRUS_Patient_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_LTRUS_Telephone Interview_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_PT_Digital Interviewer_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_PT_Patient_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_RO_Patient_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_EQ-5D-5L_RO_Telephone Interviewer_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_PROMIS-29_BEFR_2022-501419-15-00 | 2.1 |
| Protocol (for publication) | D4_PRO_PROMIS-29_BENL_2022-501419-15-00 | 2.1 |
| Protocol (for publication) | D4_PRO_PROMIS-29_DE_2022-501419-15-00 | 2.1 |
| Protocol (for publication) | D4_PRO_PROMIS-29_EL_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_PROMIS-29_ES_2022-501419-15-00 | 2.1 |
| Protocol (for publication) | D4_PRO_PROMIS-29_FR_2022-501419-15-00 | 2.1 |
| Protocol (for publication) | D4_PRO_PROMIS-29_HR_2022-501419-15-00 | 0.01 |
| Protocol (for publication) | D4_PRO_PROMIS-29_HU_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_PROMIS-29_IT_2022-501419-15-00 | 2.1 |
| Protocol (for publication) | D4_PRO_PROMIS-29_LT_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_PROMIS-29_LTRUS_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_PROMIS-29_PT_2022-501419-15-00 | 1.00 |
| Protocol (for publication) | D4_PRO_PROMIS-29_RO_2022-501419-15-00 | 1.00 |
| Recruitment arrangements (for publication) | K0_Cover letter SM-1_san | N/A |
| Recruitment arrangements (for publication) | K0_Cover letter_Bulgaria_Non-SM-1_san | N/A |
| Recruitment arrangements (for publication) | K0_Cover letter_Bulgaria_RA_Part II_san | N/A |
| Recruitment arrangements (for publication) | K0_Cover Letter_Bulgaria_SM-3_san | N/A |
| Recruitment arrangements (for publication) | K0_Cover Letter_Bulgaria_SM-4_san | N/A |
| Recruitment arrangements (for publication) | K0_Cover Letter_Bulgaria_SM-5 | N/A |
| Recruitment arrangements (for publication) | K1_ Recruitment arrangements_Pre-Consent Study Overview Animation Storyboard- san_red | V01SVK-sk |
| Recruitment arrangements (for publication) | K1_2022-501419-15_Recruitment Arrangements_FRA_San | 2 |
| Recruitment arrangements (for publication) | K1_70033093AFL3002_Netherlands_Template recruitment procedure_NLD_san | N/A |
| Recruitment arrangements (for publication) | K1_70033093AFL3002_Recruitment arrangements_Spain | 3 |
| Recruitment arrangements (for publication) | K1_Patient Brochure_Redacted | 01 |
| Recruitment arrangements (for publication) | K1_Patient Brochure_TC_redacted_san | 01 |
| Recruitment arrangements (for publication) | K1_Pre-Consent Study Overview Animation Storyboard_redacted | 01 |
| Recruitment arrangements (for publication) | K1_Recruitment and ICF Procedure_cs_san | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements Informed consent procedure_san | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_BEL_san | V3.1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_BG_san | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_Croatia_san | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_san | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_Greece_San | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_PL_san | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_Recruitment procedure_san | v3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | V4.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | 3.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | V3-0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | N/A |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | V4.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_san | V3.0 |
| Recruitment arrangements (for publication) | K2_2022-501419-15_Recruitment Material_Banner Ads_FRA_not dated_San | NA |
| Recruitment arrangements (for publication) | K2_2022-501419-15_Recruitment Material_Patient Brochure_FRA_Red_San | V01FRAfr |
| Recruitment arrangements (for publication) | K2_2022-501419-15_Recruitment Material_Pre-Consent Storyboard_FRA_Red_San | V01FRA(fr) |
| Recruitment arrangements (for publication) | K2_2022-501419-15_Recruitment Material_Social Media and Clinical Trial Posts_FRA_San | V01FRA(fr) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_banner Ads_san | NA |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Appointment Cancellation Request Call Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Appointment Request with Warm Transfer Call Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Direct Mail Letter_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Email_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_ePR Participant Journey Emails_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Inbound Call Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Marketing and Outreach Content_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Outbound Call Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Patient Pre-screening Website Content_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Print Ads Large_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Print Ads Small_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Radio Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Schedule Appointment Call Script Inbound_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Schedule Appointment Call Script Outbound_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Study Closed Inbound Call Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_TV Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_DTP_Warm Transfer New Site Call Script_NLD | V01NLD(nl) |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Pre-Consent Study Overview Animation Storyboard_red-san | V01NLD |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Recruitment Material_Banner Ads_san | 1 |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Recruitment material_Brochure_red-san | V01NLD01 |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Recruitment Material_Patient Brochure_Red | 1 |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Recruitment Material_Social Media Clinical Trial Posts_14Jul2023_san | 1 |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Recruitment Material_Study Overview Animation Storyboard_Red_san | 1 |
| Recruitment arrangements (for publication) | K2_70033093AFL3002_Social Media and Clinical Trial Posts_san | V01 |
| Recruitment arrangements (for publication) | K2_Librexia AF_Banner Ads | 1 |
| Recruitment arrangements (for publication) | K2_Librexia AF_Banner Ads_San | 1.0 |
| Recruitment arrangements (for publication) | K2_Librexia AF_Pre-Consent Study Overview Animation Storyboard_red_san | 1 |
| Recruitment arrangements (for publication) | K2_Librexia AF_Pre-Consent Study Overview Animation Storyboard_redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_LIBREXIA AF_Social Media Clinical Trial Posts | 1 |
| Recruitment arrangements (for publication) | K2_Other subject information material_Patient Brochure_red and san | V1.0 |
| Recruitment arrangements (for publication) | K2_Patient Brochure_V01 GR_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_RecruitMat_Closed Inbound Call Script_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Direct Mail Letter_san | V01DEUde01 |
| Recruitment arrangements (for publication) | K2_RecruitMat_DTP Email_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_DTP Radio Script_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_DTP TV Script_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Inbound Call Script_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Large Newspaper Ad_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Outbound Call Script_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Outreach and Advertising_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Participant Journey Emails_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Patient Brochure_red-san | 01 DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Patient Pre-screening Website_san | V01DEUde01 |
| Recruitment arrangements (for publication) | K2_RecruitMat_Schedule Appointment Inbound Call_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Schedule Appointment Outbound Call_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Small Newspaper Ad_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Study Appointment Cancellation_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Study Appointment Request Warm_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_RecruitMat_Warm Transfer New Site Call Script_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_Recruitment arrangements_upd_San | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment mat_Animation_red-san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_Recruitment mat_Banner Ads_san | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment mat_Social Media_san | V01DEU(de) |
| Recruitment arrangements (for publication) | K2_Recruitment Material Banner Ads_san | N/A |
| Recruitment arrangements (for publication) | K2_Recruitment Material Patient Animation Storyboard_san_redacted | V01 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Patient Brochure _san_Redacted | V01 DNK01 |
| Recruitment arrangements (for publication) | K2_Recruitment Material Social Media Posts_san | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Appointment Cancellation Request Call Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Appointment Request with Warm Transfer Call Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Banner Ads_EN | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_EST_et_01 | EST(et)02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_EST_ru_01 | EST(ru)02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_lt_san | N/A |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Banner Ads_RO | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_ru_san | N/A |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_ru_TCert_redacted | N/A |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_san | N/A |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_V01_LVA_lv_11Apr2023_san | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner Ads_V01_LVA_ru_11Apr2023_san | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Banner_san | POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Birthday Card_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Birthday Card_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Direct Mail Letter_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email Birthday Card_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email Birthday Card_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email_Milestone Letter_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email_Milestone Letter_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email_Thank You Card_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Email_Thank You Card_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_ePR Participant Journey Emails_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Inbound Call Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Librexia AF_Pre-Consent Study Overview Animation Storyboard_EE_redacted | 01EST02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Librexia AF_Pre-Consent Study Overview Animation Storyboard_RU_redacted | 01EST02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_LIBREXIA AF_Social Media and Clinical Trial Posts_EE | 01EST02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_LIBREXIA AF_Social Media and Clinical Trial Posts_RU | 01EST02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Milestone Letter_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Milestone Letter_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Online Banner Ad_SK | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Outbound Call Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_BGR_red-san | 01 BGR(bg) |
| Recruitment arrangements (for publication) | K2_Recruitment material_patient brochure_EE_Redacted | V01EST03 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Brochure_EN_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_ENG_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_HRV_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_lt_red | V01LTU(lt) |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Brochure_Red | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Brochure_Red | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Brochure_Red | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_red_san | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_red_san | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_Red_San | V01 ITAit |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_red-san | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Patient Brochure_RO_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_ru_red | V01LTU(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_patient brochure_RU_Redacted | V01EST03 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Brochure_ru_TCert_Redacted | V01LTU(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient ID Card_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient ID Card_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Pre-screening Website Content_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Welcome Letter_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patient Welcome Letter_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Patients Brochure_Redacted | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Pre-Consent Study Overview Animation Storyboard_EN_redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_lt_redacted | V01LTU(lt) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_red_san | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_red_san | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_red-san | 01 BGR(bg) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_Redacted | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Pre-Consent Study Overview Animation Storyboard_RO_redacted | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_ru_redacted | V01LTU(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-Consent Study Overview Animation Storyboard_ru_TCert_redacted | NA |
| Recruitment arrangements (for publication) | K2_Recruitment material_Pre-consent Study Overview Animation Storyboard_V01_hr_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Print Ads Large_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Print Ads Small_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Radio Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Schedule Appointment Call Script Inbound_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Schedule Appointment Call Script Outbound_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_lt_san | V01LTU(lt) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_ru_san | V01LTU(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_ru_TCert_redacted | N/A |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_san | V01LVA02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_san | V01LVA02 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Social Media and Clinical Trial Posts_san | 01 BGR(bg) |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Social Media Clinical Trial Posts_EN | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Social Media Clinical Trial Posts_RO | 01 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Study Closed Inbound Call Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Study Welcome Folder_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Study Welcome Folder_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Thank You Card_san_lv | V01LVA(lv) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Thank You Card_san_ru | V01LVA(ru) |
| Recruitment arrangements (for publication) | K2_Recruitment material_TV Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment material_Warm Transfer New Site Call Script_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K2_Recruitment_Outreach and Advertising_Content Selections for Translation_PL_san | V01POL(pl) |
| Recruitment arrangements (for publication) | K3_Recruitment Material_Banner Ads_San | 1 |
| Recruitment arrangements (for publication) | K3_Recruitment Material_Banner Ads_San | 1 |
| Recruitment arrangements (for publication) | K3_Recruitment Material_Banner Ads_San | 1 |
| Recruitment arrangements (for publication) | K4_Recruitment Material_Pre consent Animation Storyboard_San_Redacted | 1 |
| Recruitment arrangements (for publication) | K4_Recruitment Material_Pre consent Animation Storyboard_San_Redacted | 1 |
| Recruitment arrangements (for publication) | K4_Recruitment Material_Pre consent Animation Storyboard_San_Redacted | 1 |
| Recruitment arrangements (for publication) | K5_Recruitment Material_Social Media and Clinical Trial Post_Dutch_San | V01BEL01 |
| Recruitment arrangements (for publication) | K5_Recruitment Material_Social Media and Clinical Trial Post_English_San | V01BEL01 |
| Recruitment arrangements (for publication) | K5_Recruitment Material_Social Media and Clinical Trial Post_French_San | V01BEL01 |
| Subject information and informed consent form (for publication) | L1_1_1_SIS and ICF Main Master_red-san | 5.0 |
| Subject information and informed consent form (for publication) | L1_1_2_SIS and ICF_Main ICF_EN_red-san | 1.0 |
| Subject information and informed consent form (for publication) | L1_1_3_SIS and ICF_Main ICF_BG_red-san | V5.0BGR1.0 |
| Subject information and informed consent form (for publication) | L1_2_1_SIS and ICF_Pregnant Partner ICF_Master_san | V1.1 |
| Subject information and informed consent form (for publication) | L1_2_2_SIS and ICF_Pregnant Partner ICF_EN_san | 1.0 |
| Subject information and informed consent form (for publication) | L1_2_3_SIS and ICF_Pregnant Partner ICF_BG_san | V1.1BGR1.0 |
| Subject information and informed consent form (for publication) | L1_2022-501419-15_ICF_Main_FRA_San | V5.0FRA1.0 |
| Subject information and informed consent form (for publication) | L1_2022-501419-15_ICF_Pregnancy FU_FRA_San | V1.1FRA3.0 |
| Subject information and informed consent form (for publication) | L1_70033093AFL3002_Main ICF_NLD_red-san | V5.0NLD2.0 |
| Subject information and informed consent form (for publication) | L1_70033093AFL3002_Main ICF_Red | V5.0ESP2.0 |
| Subject information and informed consent form (for publication) | L1_70033093AFL3002_Pregnancy ICF NLD_red-san | V1.1NLD1.0 |
| Subject information and informed consent form (for publication) | L1_70033093AFL3002_Pregnant Partner ICF_san | V1_1ESPes1 |
| Subject information and informed consent form (for publication) | L1_Croatia_Informed consent Pregnant Partner_eng_san | 1 |
| Subject information and informed consent form (for publication) | L1_Croatia_Informed consent Pregnant Partner_hr_san | 2 |
| Subject information and informed consent form (for publication) | L1_Croatia_Informed consent Pregnant Subject_eng_san | 1 |
| Subject information and informed consent form (for publication) | L1_Croatia_Informed consent Pregnant Subject_hr_san | V1.1HRV2.0 |
| Subject information and informed consent form (for publication) | L1_Croatia_Main Informed consent_eng_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Croatia_Main Informed consent_hr_Redacted | V5.0HRV2.0 |
| Subject information and informed consent form (for publication) | L1_Main GDPR ICF_cs_red and san | CZEcs3.0 |
| Subject information and informed consent form (for publication) | L1_Main GDPR ICF_FINAL_enrolled patient_cs_red and san | CZEcs3.0 |
| Subject information and informed consent form (for publication) | L1_Main ICF_cs_red and san | V5.0CZE2.0 |
| Subject information and informed consent form (for publication) | L1_Main ICF_red and san | 5.0SVK2.0 |
| Subject information and informed consent form (for publication) | L1_Main_ICF_red-san | V5DEUde1 |
| Subject information and informed consent form (for publication) | L1_PP ICF_sk_san | V1.1SVK3.0 |
| Subject information and informed consent form (for publication) | L1_PP_ICF_red-san | N/A |
| Subject information and informed consent form (for publication) | L1_Pregnant Partner GDPR ICF_cs_red and san | CZEcs1.1 |
| Subject information and informed consent form (for publication) | L1_Pregnant Partner ICF_cs_san | V1.1CZEcs |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Clean_ENG_Redacted | v5.0GRC3.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Clean_GRC_Redacted | v5.0GRC3.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_LTU_lt_redacted | V5.0LTU2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_LTU_ru_redacted | V5.0LTU2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_LTU_ru_TCert | NA |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_lv_san | V05LATlv01 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | V5.0POL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_ru_san | V05LATru01 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_ru_TCert_san | V3.0LTU3.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_san_Redacted | V5.0DNK2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF PP_red_san | 1.1LATLV01 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF PP_red_san | 1.1LATRU01 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF PP_san | V1.1DNK1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnant Partner_Clean_ENG_Redacted | 1.1GRC1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnant Partner_Clean_GRC_Redacted | 1.1GRC1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnant Partner_hu_clean | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pregnant Partner_san | V1.1POL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Informed Consent Form_Main_EN_red | V5.0PRT1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Informed Consent Form_Main_red-san | 5.0PRT1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Informed Consent Form_Pregnant partner_EN_red | V1.1PRT4.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Informed Consent Form_Pregnant partner_PT_red | V1.1PRT4.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_EN_red | V5.0BEL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_EN_Redacted | 5.0ROM1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_et_Redacted | 5.0EST2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_FR_red | V5.0BEL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_NL_red | V5.0BEL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_RO_Redacted | 5.0ROM1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_ru_Redacted | 5.0EST2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_hu_clean_Redacted | 5.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_hu_Clean_redacted_san | 5.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_San_Red | V5.0ITA1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_TC_Redacted | 4 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PP ICF_EN_clean | 1.1BEL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PP ICF_EN_san | 1.1ROM4.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PP ICF_FR_clean | 1.1BEL1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PP ICF_NL_clean | 1.1BEL1.0A |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PP ICF_RO_san | 1.1ROM4.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner ICF_et | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner ICF_ru | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner_lt_san | V1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner_ru_san | V1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner_San | V1.1ITA3.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Privacy Information Sheet for Patients Relatives or Close Friends_san | V1.0ITA1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Privacy_San_Red | V2.0ITA2.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Sponsor statement on the use of ICF_Red | 1 |
| Subject information and informed consent form (for publication) | L2_1_Other subject information_Patient ID Card_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Birthday Card_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Email Message - Birthday Card_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Email Message - Milestone Letter_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Email Message - Thank You Card_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject information material_Email Message Newsletter1_BGR_Blank page for publication | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject information material_Medication Instruction Card_BGR_Blank page for publication | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Milestone Letter_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject information material_Participant Newsletter Issue 2_BGR | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject information material_Participant Newsletter Issue 3_BGR | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject information material_ParticipantNewsletter Issue1_BGR_Blank page for publication | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Patient Welcome Letter_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject Information material_Thank You Card_BGR_san | 01 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2_Other subject information_Patient Study Guide_BGR_red-san | 04 BGR(bg) |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Important Patient Notice_FRA_san | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Birthday Card Email_FRA_San | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Birthday Card_FRA_San | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Milestone Letter Email_FRA_San | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Milestone Letter_FRA_San | V01FRAfr01 |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Patient ID Card_FRA_San | V02FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Patient Study Guide_FRA_statement | N/A |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Patient Welcome Letter_FRA_San | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Study Welcome Folder_FRA_San | V01USAen |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Tablet Instructions_FRA_San | V3 |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Tablet Training Module T_FRA_San | v1-00 |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Tablet Training Module TO_FRA_San | v1-00 |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Thank You Card Email_FRA_San | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_2022-501419-15_Patient_Thank You Card_FRA_San | V01FRAfr |
| Subject information and informed consent form (for publication) | L2_3_ EQ-5D-5L Paper Telephone_Draft_Screenshot_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_ EQ-5D-5L Paper Telephone_san | N/A |
| Subject information and informed consent form (for publication) | L2_3_eCOA Tablet_TrainingModuleT_Bulgarian_Mandatory_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_eCOA Tablet_TrainingModuleTO_Bulgarian_Optional_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_EQ-5D-5L Digital Self-Complete_Draft_Screenshot_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_EQ-5D-5L Digital Self-Complete_san | N/A |
| Subject information and informed consent form (for publication) | L2_3_PRO_AE_BG_Patient Instructions_Draft Screenshot_After Completion_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_PRO_AE_BG_Patient Instructions_Draft Screenshot_Prior Completion_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_PRO_AE_Text_BG_Patient Instructions_san | 3 |
| Subject information and informed consent form (for publication) | L2_3_PROMIS-29 Profile_BUL_Draft_Screenshot_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_3_PROMIS-29 Profile_BUL_san | N/A |
| Subject information and informed consent form (for publication) | L2_Birthday Card | 01 |
| Subject information and informed consent form (for publication) | L2_eCOA Tablet_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_eCOA Tablet_Participant Instructions_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_eCOA Tablet_PI_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_eCOA Tablet_PROMIS-29_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_eCOA Tablet_TrainingModuleT_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_eCOA Tablet_TrainingModuleTO_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_Effective_Hungary_EQ-5D-5L Digital Interviewer Administration | 1.0 |
| Subject information and informed consent form (for publication) | L2_Effective_Hungary_EQ-5D-5L Digital Self-Complete | 1.0 |
| Subject information and informed consent form (for publication) | L2_Email Message - Birthday Card | 01 |
| Subject information and informed consent form (for publication) | L2_Email Message - Milestone Letter | 01 |
| Subject information and informed consent form (for publication) | L2_Email Message - Thank You Card | 01 |
| Subject information and informed consent form (for publication) | L2_EQ-5D-5L_eCOA Tablet_Hungarian | 1.00 |
| Subject information and informed consent form (for publication) | L2_Important Patient Notice_hu_san | 01 |
| Subject information and informed consent form (for publication) | L2_Memo_Hungary | 1 |
| Subject information and informed consent form (for publication) | L2_Milestone Letter_A4 | 01 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material Your rights_san | N/A |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Banner Ads_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Birthday Card_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_Participant Instructions_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_Participant Instructions_san | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_eCOA Tablet_Participant Instructions_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_PI_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_PI_san | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_eCOA Tablet_PI_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_PROMIS-29_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_eCOA Tablet_PROMIS-29_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_TrainingModuleT_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_TrainingModuleT_san | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_eCOA Tablet_TrainingModuleT_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_TrainingModuleTO_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_eCOA Tablet_TrainingModuleTO_san | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_eCOA Tablet_TrainingModuleTO_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Email Message - Birthday Card_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Email Message - Milestone Letter_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Email Message - Thank You Card_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Email Message_Patient Newsletter_blank page | N/A |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_EQ-5D-5L_eCOA Tablet_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_EQ5D5L Digital Interviewer Administration_cs_san | V1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_EQ5D5L Digital Self-Complete_cs_san | V1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_EQ5D5L eCOA Tablet_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_EQ5D5LIT_eCOA Tablet_cs_san | 0.01 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_EQ5D5LITT_eCOA Tablet_SVK_v1_00 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_GP Letter_Red_San | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Important Patient Notice | V01PRT(pt) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Important Patient Notice_EN | V01PRT(en) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Medication Instruction Card_blank page | N/A |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Medication Instruction Card_EN | V01PRT(en) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Milestone Letter_cs_san | V01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Participant Newsletter Issue 1_blank page | N/A |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Participant Newsletter Issue 2_san | V01PRT01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Participant Newsletter Issue 3_san | V01PRT01 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Participant Newsletter Issue 4_san | 01PRT1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Brochure_cs_red and san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient card_san | V01 ITAit |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient ID Card_cs_san | V02 CZE |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient ID Card_EN | V02PRT(en) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient ID Card_san | V02PRT(pt) |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Patient ID Card_SVK | 02 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Study Guide_cs_red and san | V03CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Study Guide_red-san | N/A |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Welcome Letter_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Pre-Consent Study Overview Animation Storyboard_cs_red and san | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_PRO_AE_Text_cs_san | czech |
| Subject information and informed consent form (for publication) | L2_Other subject information material_PROMIS-29 Profile_cs_san | V2.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Social Media and Clinical Trial Posts_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Welcome Folder_cs_san | V01USA(en) |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Thank You Card_cs_san | V01CZE(cs) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Birthday Card_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Birthday Card_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_Participant Instructions_lt | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_Participant Instructions_ru | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_PI_lt | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_PI_ru | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_TrainingModuleT_lt | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_TrainingModuleT_ru | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_TrainingModuleTO_lt | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_eCOA Tablet_TrainingModuleTO_ru | 1.00 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Email Message-Birthday Card_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Email Message-Birthday Card_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Email Message-Milestone Letter_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Email Message-Milestone Letter_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Email Message-Thank You Card_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Email Message-Thank You Card_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_for publication placeholder | NA |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Important Patient Notice_LTU_lt | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Important Patient Notice_LTU_ru | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Milestone Letter_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Milestone Letter_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Participant Newsletter Issue 2_LTU_lt | V01LTU02 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Participant Newsletter Issue 2_LTU_ru | V01LTU02 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Participant Newsletter Issue 3_LTU_lt | V01LTU02 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Participant Newsletter Issue 3_LTU_ru | V01LTU02 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Participant Newsletter Issue 4_LTU_lt | V01LTU01 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Participant Newsletter Issue 4_LTU_ru | V01LTU01 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient ID Card_LTU_lt | V02LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient ID Card_LTU_ru | V02LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Study Guide_lt_red | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Study Guide_LTU_lt | V04LTU01 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Study Guide_LTU_ru | V04LTU01 |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Study Guide_ru_red | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Study Guide_ru_TCert_Redacted | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Welcome Letter_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Patient Welcome Letter_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Thank You Card_lt_san | V01LTU(lt) |
| Subject information and informed consent form (for publication) | L2_Other subject information materials_Thank You Card_ru_san | V01LTU(ru) |
| Subject information and informed consent form (for publication) | L2_Participant Newsletter Issue 2_san | 01 |
| Subject information and informed consent form (for publication) | L2_Participant Newsletter Issue 3_san | 01 |
| Subject information and informed consent form (for publication) | L2_Participant Newsletter Issue 4_hu_san | 01 |
| Subject information and informed consent form (for publication) | L2_Patient ID Card | 02 |
| Subject information and informed consent form (for publication) | L2_Patient Welcome Letter | 01 |
| Subject information and informed consent form (for publication) | L2_PRO_AE_Text_HU-hun | 3 |
| Subject information and informed consent form (for publication) | L2_PROMIS-29 Profile_HUN | 2.1 |
| Subject information and informed consent form (for publication) | L2_Study Assistance Items | 01 |
| Subject information and informed consent form (for publication) | L2_Study Guide for Patients and Caregivers_Redacted | 01 |
| Subject information and informed consent form (for publication) | L2_Study Welcome Folder | 01 |
| Subject information and informed consent form (for publication) | L2_Thank You Card | 01 |
| Subject information and informed consent form (for publication) | L3_List of modified documents_en | 2 |
| Subject information and informed consent form (for publication) | L3_List of modified documents_hu | 2 |
| Subject information and informed consent form (for publication) | L3_List of modified documents_hu_en_san | 1 |
| Subject information and informed consent form (for publication) | L3_List of submitted documents_en | 1 |
| Subject information and informed consent form (for publication) | L3_List of submitted documents_hu | 1 |
| Summary of Product Characteristics (SmPC) (for publication) | E2_SMPC_Eliquis_apixaban | N/A |
| Summary of Product Characteristics (SmPC) (for publication) | G2_US Prescribing Information_Eliquis_apixaban | N/A |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_BEDE_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_BEFR_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_BENL_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_BG_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_CZ_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_DE_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_EL_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_EN_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_ES_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_FR_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_HU_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_IT_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_LT_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_NL_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_PL_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_PT_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_RO_2022-501419-15-00 | Am 3 |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_SK_2022-501419-15-00 | Am 3 |
Application history
34 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2023-04-11 | Belgium | Acceptable 2023-08-07
|
2023-08-07 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2023-08-15 | Acceptable 2023-08-07
|
2023-08-15 | |
| 3 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2023-08-15 | Acceptable 2023-08-07
|
2023-08-15 | |
| 4 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2023-08-16 | Acceptable 2023-08-07
|
2023-08-16 | |
| 5 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2023-08-16 | Acceptable 2023-08-07
|
2023-08-16 | |
| 6 | SUBSTANTIAL MODIFICATION | SM-1 | 2023-09-14 | Belgium | Acceptable 2023-11-20
|
2023-11-21 |
| 7 | NON SUBSTANTIAL MODIFICATION | NSM-6 | 2023-12-19 | Acceptable 2023-11-20
|
2023-12-19 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-2 | 2024-01-09 | Acceptable | 2024-02-07 | |
| 9 | NON SUBSTANTIAL MODIFICATION | NSM-7 | 2024-02-13 | 2024-02-13 | ||
| 10 | NON SUBSTANTIAL MODIFICATION | NSM-8 | 2024-02-14 | 2024-02-14 | ||
| 11 | NON SUBSTANTIAL MODIFICATION | NSM-9 | 2024-02-16 | Belgium | 2024-02-16 | |
| 12 | NON SUBSTANTIAL MODIFICATION | NSM-10 | 2024-02-23 | 2024-02-23 | ||
| 13 | NON SUBSTANTIAL MODIFICATION | NSM-11 | 2024-02-27 | 2024-02-27 | ||
| 14 | SUBSTANTIAL MODIFICATION | SM-3 | 2024-03-15 | Belgium | Acceptable 2024-06-03
|
2024-06-03 |
| 15 | NON SUBSTANTIAL MODIFICATION | NSM-12 | 2024-06-19 | 2024-06-19 | ||
| 16 | NON SUBSTANTIAL MODIFICATION | NSM-13 | 2024-07-19 | 2024-07-19 | ||
| 17 | NON SUBSTANTIAL MODIFICATION | NSM-14 | 2024-08-28 | 2024-08-28 | ||
| 18 | NON SUBSTANTIAL MODIFICATION | NSM-15 | 2024-09-16 | 2024-09-16 | ||
| 19 | NON SUBSTANTIAL MODIFICATION | NSM-16 | 2024-09-17 | 2024-09-17 | ||
| 20 | NON SUBSTANTIAL MODIFICATION | NSM-17 | 2024-09-19 | 2024-09-19 | ||
| 21 | NON SUBSTANTIAL MODIFICATION | NSM-18 | 2024-09-24 | 2024-09-24 | ||
| 22 | SUBSTANTIAL MODIFICATION | SM-4 | 2024-10-11 | Belgium | Acceptable 2025-01-24
|
2025-01-24 |
| 23 | SUBSTANTIAL MODIFICATION | SM-5 | 2025-04-24 | Belgium | Acceptable 2025-07-22
|
2025-07-28 |
| 24 | SUBSTANTIAL MODIFICATION | SM-6 | 2025-09-01 | Acceptable | 2025-10-16 | |
| 25 | SUBSTANTIAL MODIFICATION | SM-8 | 2025-09-02 | Acceptable | 2025-10-14 | |
| 26 | SUBSTANTIAL MODIFICATION | SM-7 | 2025-09-03 | Acceptable | 2025-09-16 | |
| 27 | SUBSTANTIAL MODIFICATION | SM-9 | 2025-09-17 | Acceptable | 2025-10-14 | |
| 28 | SUBSTANTIAL MODIFICATION | SM-10 | 2025-09-25 | Acceptable | 2025-10-21 | |
| 29 | SUBSTANTIAL MODIFICATION | SM-11 | 2025-10-02 | Acceptable | 2025-10-29 | |
| 30 | SUBSTANTIAL MODIFICATION | SM-12 | 2025-12-02 | Acceptable | 2026-03-02 | |
| 31 | SUBSTANTIAL MODIFICATION | SM-13 | 2025-12-09 | Acceptable | 2026-02-06 | |
| 32 | SUBSTANTIAL MODIFICATION | SM-14 | 2025-12-22 | Acceptable | 2026-02-04 | |
| 33 | SUBSTANTIAL MODIFICATION | SM-15 | 2026-01-30 | Acceptable | 2026-03-11 | |
| 34 | SUBSTANTIAL MODIFICATION | SM-16 | 2026-03-16 | Belgium | Acceptable 2026-05-08
|
2026-05-08 |